Predictive value of angiogenic factors, clinical risk factors and uterine artery Doppler for pre-eclampsia and fetal growth restriction in second and third trimester pregnancies in an Ecuadorian population

Kienast, Carolin; Moya, Walter; Rodríguez, Oswaldo Tipiani; Jijon, Alfredo; Geipel, A.

doi:10.3109/14767058.2015.1012063

Cited by 26 publications

(22 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These markers and their ratio are important in clinical monitoring of patients with preeclampsia, and they are used on a regular basis [35][36][37]. The Flt-1/PIGF ratio is increasingly used in the study of restricted intrauterine growth [38]. All these pathological events are associated with hypoxic processes affecting placental vascularisation [19].…”

Section: Discussionmentioning

confidence: 99%

Increased Angiogenesis and Lymphangiogenesis in the Placental Villi of Women with Chronic Venous Disease during Pregnancy

Ortega

Sáez

Fraile-Martínez

et al. 2020

IJMS

View full text Add to dashboard Cite

Pregnancy is a period in a woman’s life associated with an increased risk of developing lower extremity chronic venous disease (CVD). Pregnancy-associated CVD is associated with changes in placental villi. We investigated angiogenesis and lymphangiogenesis in the placental villi of women with CVD during pregnancy compared with healthy controls with no history of CVD (HC). An observational, analytical, and prospective cohort study was conducted on 114 women in their third trimester of pregnancy (32 weeks). Sixty-two participants were clinically diagnosed with CVD. In parallel, 52 controls with no history of CVD (HC) were studied. Gene and protein expression of CD31, podoplanin (D2-40), Flt-1, and placental growth factor (PIGF) was analysed by real-time polymerase chain reaction (RT-qPCR) and immunohistochemistry. CD31 and D2-40 gene expression was significantly greater in the placental villi of women with CVD, as were the numbers of vessels positive for CD31 and D2-40. Significantly higher gene and protein expression of Flt-1 and PIGF was observed in the placental villi of women with CVD. Histological analysis showed more placental villi with periodic acid of Schiff (PAS)-positive material in women with CVD. Our results show a connection between pregnancy-associated CVD and leading to higher proangiogenic and lymphangiogenic activity in placental villi.

show abstract

Section: Discussionmentioning

confidence: 99%

Increased Angiogenesis and Lymphangiogenesis in the Placental Villi of Women with Chronic Venous Disease during Pregnancy

Ortega

Sáez

Fraile-Martínez

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Twenty-six studies (total participants, N = 42,609) were deemed to be eligible for final inclusion. Of these, 21 studies reported the relationship between PlGF and SGA or FGR infants with a participant total of N = 41,837 (10,13,(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39)(40)(41)(42), seven studies detailed the predictive value of PlGF for other adverse perinatal outcomes with a participant total of N = 13,401 (8,10,13,14,25,38,43) and three studies described the role of PlGF in distinguishing between placentally-mediated FGR and constitutionally SGA infants with a participant total of N = 841 (10,44,45). Table 1 and include the type of study, populations of recruited women, total number of participants, gestation at which PlGF was measured, type of PlGF assay, criteria for abnormal maternal PlGF levels if defined and specific outcomes investigated.…”

Section: Study Selectionmentioning

confidence: 99%

Systematic review of maternal Placental Growth Factor levels in late pregnancy as a predictor of adverse intrapartum and perinatal outcomes

Sherrell

Dunn

Clifton

et al. 2018

European Journal of Obstetrics & Gynecology and Reproductiv

View full text Add to dashboard Cite

Low maternal PlGF levels in late pregnancy are strongly associated with SGA. Findings across studies were variable in relation to PlGF and the prediction of other adverse intrapartum and perinatal outcomes, however there was a consistent association between low PlGF levels and CS for fetal compromise, NICU admission and stillbirth. This review suggests that the use of PlGF for the prediction of adverse outcomes is promising. Its predictive value may potentially be enhanced if used in combination with other biomarkers or biophysical measures of fetal well-being.

show abstract

“…[65] [66] It is combined with measurements of the middle cerebral artery systolic/diastolic ratio, resistance index and pulsatility index. High uterine artery pulsatility index > 0.58 may be considered abnormal.…”

Section: Diagnosis Of Pre-eclampsiamentioning

confidence: 99%

Adjunctive Use of Esomeprazole in the Treatment of Pre-Eclampsia: A Case Report and Literature Review

Oriaifo¹

2017

WJPPS

View full text Add to dashboard Cite

Faced with the absence of suitable assays and/or kits for predictive biomarkers, medical practitioners in poor resource settings may be emasculated by the unrelenting upwards prevalence of and uncertain forecast associated with the pre-eclampsia/eclampsia and fetal growth restriction disease spectrum. Low-birth weight and pre-eclampsia due to placental malaria, multiple pregnancy and malnutrition may be reactive oxygen species -and anti-angiogenic factors -dependent.Adjunctive esomeprazole promises to be a treatment regimen that may lead to cure for it has been found to attenuate the known pathophysiologic mechanisms responsible for pre-eclampsia and IUGR which may be imbalance between pro-angiogenic and anti-angiogenic factors. The proton pump inhibitor, esomeprazole, decreases the excessive secretion of the anti-angiogenic factors soluble fmslike tyrosine kinase-I (sFlt-I) and soluble endoglin from the placenta responsible for the hypertension, endothelial dysfunction, multiorgan injury and foetal growth restriction in preeclampsia. sFlt-I binds the pro-angiogenic placenta growth factor (PIGF) and vascular endothelial growth factor (VEGF), the circulating free forms of which are low in preeclampsia. Case report is of a 32-year old Nigerian housewife who showed significant reduction in blood pressure, proteinuria and pedal oedema with esomeprazole add-on to a regimen of methyl-dopa for severe preeclampsia. The combination significantly (P < 0.05) This report corroborates the accumulating pre-clinical data on the safety and efficacy of esomeprazole in the treatment of preeclampsia, a precursor of eclampsia.

show abstract

Predictive value of angiogenic factors, clinical risk factors and uterine artery Doppler for pre-eclampsia and fetal growth restriction in second and third trimester pregnancies in an Ecuadorian population

Abstract: In a high-altitude Ecuadorian population, angiogenic factors and UA PI were useful tools in the prediction of PE and/or FGR. The highest performance was achieved by the combination of these factors, including obstetric and medical history.

Cited by 26 publications

References 39 publications

Increased Angiogenesis and Lymphangiogenesis in the Placental Villi of Women with Chronic Venous Disease during Pregnancy

Increased Angiogenesis and Lymphangiogenesis in the Placental Villi of Women with Chronic Venous Disease during Pregnancy

Systematic review of maternal Placental Growth Factor levels in late pregnancy as a predictor of adverse intrapartum and perinatal outcomes

Adjunctive Use of Esomeprazole in the Treatment of Pre-Eclampsia: A Case Report and Literature Review

Contact Info

Product

Resources

About